Marinomed Biotech

Executive Summary

Marinomed Biotech AG is a Vienna-based biopharmaceutical company focused on developing therapies for viral infectious diseases and autoreactive immune disorders using its proprietary Marinosolv® technology platform. Founded in 2006, the company leverages this platform to enhance the solubility and bioavailability of active pharmaceutical ingredients, aiming to create novel treatments with improved efficacy and safety profiles. Marinomed's lead programs target respiratory viruses, including influenza and RSV, as well as immunological conditions. The company operates privately, with a lean structure and a dedicated research team advancing its pipeline toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead antiviral candidate55% success
• Q2 2027Partnership or licensing deal for Marinosolv platform40% success
• Q1 2027Initiation of Phase 1 trial for autoimmune candidate70% success